• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Market Analysis Latest ASX News

Zelira Therapeutics Share Price Soars on Distribution Agreement

Like 0

By Lachlann Tierney, Monday, 14 December 2020

The share price of medical cannabis company Zelira Therapeutics Ltd (ASX:ZLD) has rocketed today thanks to a distribution agreement in the Washington DC area, US. At time of writing the ZLD share price is up 36.36% or 3.6 cents to trade at 13.5 cent per share...

The share price of medical cannabis company Zelira Therapeutics Ltd [ASX:ZLD] has rocketed today thanks to a distribution agreement in the Washington DC area, US.

At time of writing the ZLD share price is up 36.36% or 3.6 cents to trade at 13.5 cent per share.

ASX ZLD - Zelira Share Price

Source: Tradingview

The latest agreement has moved ZLD’s share price to its highest point since May 2018, as cannabis stocks hint at a resurgence in late 2020.

Why is this big news?

Today, the medical cannabis producer announced it had entered into a binding licensing agreement with Alternative Solutions LLC to manufacture and distribute Zelira’s ‘HOPE’ products.

Its HOPE products targets Autism Spectrum Disorder and is already launched and generating revenues in Pennsylvania, Louisiana, and Australia.

So, why are we seeing share price action from an agreement in just one state?

Washington DC has reciprocity with 32 other states in the US with approved medical cannabis programs.

Meaning ZLD’s latest deal will expand access to patients registered in all the 32 states as they can legally purchase medical cannabis products at an approved dispensary in Washington DC.

Quite a large increase in its consumer market.

Under the terms of the licensing agreement, ZLD will receive an upfront fee and ongoing royalties from HOPE product sales in Washington DC.

The company said its focus is now on expanding the distribution of HOPE through licensing agreements in each approved market across the US next year, as the COVID-19 pandemic gets under control.

Four Innovative Aussie Stocks That Could Shoot up after Lockdown.

CEO Dr Oludare Odumosu commented:

‘Our partnership with Alternative Solution, a leader in the Washington DC market, is a strategic move in line with our mission of working with market leaders in approved markets to expand access to HOPE across the USA.

‘We are particularly excited about this partnership because Washington DC is a gateway state with over 24 million visitors passing though the US capital in a year. Washington DC’s reciprocity is a strategic move that allows approved patients from 32 states to legally access HOPE™ in DC.’

Will we see a resurgence in the Zelira share price next year?

ZLD shares are nearly back to their 2018 peak having returned 123% in the past 12 months.

The COVID-19 virus has seen plenty of interest return to medical stocks, even those that are not directly related to battling the pandemic.

With a more health-conscious population emerging from the current pandemic, we could see stocks like ZLD enjoy a nice uplift in price.

If you’re searching for high-value stocks, then be sure to check out this report where we breakdown the four Aussie small-caps stocks that are well positioned to capitalise in the post-COVID world. Get your free copy here.

Regards,

Lachlann Tierney

For Money Morning

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Lachlann Tierney

Lachlann’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • China’s Game of Commodity Chicken
    By Charlie Ormond

    When commodities become weapons instead of just market goods, traditional investing rules break down.

  • Ride Mining’s Profitable ‘Curve’ this Way
    By Callum Newman

    All week we’ve been on a mission. We’re unpicking the dynamics around gold, and gold stocks. Here’s a bit of advice on this opportunity,

  • Silver & Platinum Squeeze Higher
    By James Cooper

    Cycle Turns: Silver and Platinum on the move… Is it their industrial or precious metal angle that’s getting investors interested?

Primary Sidebar

Latest Articles

  • China’s Game of Commodity Chicken
  • Ride Mining’s Profitable ‘Curve’ this Way
  • Silver & Platinum Squeeze Higher
  • One forecast for gold: 10k per ounce!
  • Three men, $20.8 million, and a $230 million rally… all in a day

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988